At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 06-05 16:00:00 EDT
15.84
-0.53
-3.24%
盘后16.05
+0.21+1.33%
19:41 EDT
High16.70Low15.82Vol1.28M
Open16.46D1 Closing16.37Amplitude5.38%
Mkt Cap2.04BTradable Cap2.03BTotal Shares128.60M
T/O20.57MT/O Rate1.00%Tradable Shares128.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook
Simply Wall St.  ·  05:32
Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook
Aurinia Pharmaceuticals holds annual shareholder meeting
Reuters  ·  06-05 04:19
Aurinia Pharmaceuticals holds annual shareholder meeting
Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis
TIPRANKS  ·  06-04 19:05
Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis
Aurinia says Lupkynis cuts renal-related event or death risk 53% in AURORA 1 lupus nephritis analysis
Reuters  ·  06-04 19:01
Aurinia says Lupkynis cuts renal-related event or death risk 53% in AURORA 1 lupus nephritis analysis
Lupkynis Associated With a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
THOMSON REUTERS  ·  06-04 19:00
Lupkynis Associated With a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
Aurinia Pharmaceuticals up 4% in pre-market after insider transactions
TIPRANKS  ·  06-03
Aurinia Pharmaceuticals up 4% in pre-market after insider transactions
Aurinia Pharmaceuticals CEO Buys $12.5 Million Worth of Shares
MT Newswires Live  ·  06-03
Aurinia Pharmaceuticals CEO Buys $12.5 Million Worth of Shares
Tang Capital Management, Llc Files Early Warning Report Respecting Aurinia Pharmaceuticals Inc.
THOMSON REUTERS  ·  06-03
Tang Capital Management, Llc Files Early Warning Report Respecting Aurinia Pharmaceuticals Inc.
Aurinia CEO Kevin Tang reports buying $13.12 million of common shares
Reuters  ·  06-03
Aurinia CEO Kevin Tang reports buying $13.12 million of common shares
Aurinia issues corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plan
Reuters  ·  05-28
Aurinia issues corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plan
Aurinia completes tender offer for Kezar, wins 80% of shares tendered
Reuters  ·  05-19
Aurinia completes tender offer for Kezar, wins 80% of shares tendered
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
TIPRANKS  ·  05-11
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-11
Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Aurinia completes Kezar acquisition at $6.96 per share plus CVR
Reuters  ·  05-11
Aurinia completes Kezar acquisition at $6.96 per share plus CVR
Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million
Reuters  ·  05-11
Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million
Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis
Reuters  ·  05-07
Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20
MT Newswires Live  ·  05-07
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20
Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million
Reuters  ·  05-07
Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million
BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million
Reuters  ·  05-07
BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million
Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln
THOMSON REUTERS  ·  05-07
Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--